Physician profile
James B Harris
NPI 1417139924
$9,527.31
in general payments reported to CMS, 2019-2025
37 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $859 · 2021: $1,200 · 2022: $3,300 · 2023: $1,152 · 2024: $1,127 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,387.19 | 2022-2024 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Novartis Pharmaceuticals Corporation | $1,484.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $865.03 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $698.61 | 2019-2025 | Lifevest |
| Pfizer INC. | $633.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $483.85 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $404.05 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.00 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $329.53 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $245.72 | 2019-2021 | |
| Astellas Pharma US INC | $193.12 | 2019-2020 | |
| Abbott Laboratories | $164.62 | 2019-2025 | Cardiomems, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $141.82 | 2025 | |
| Heartflow, INC. | $135.52 | 2022 | |
| Kestra Medical Technology Services, INC. | $128.13 | 2022-2025 | Assure Wcd |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.